Literature DB >> 10739910

An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.

S Munshi1, Z Chen, Y Yan, Y Li, D B Olsen, H B Schock, B B Galvin, B Dorsey, L C Kuo.   

Abstract

Structures of the complexes of HIV protease inhibitor L--756,423 with the HIV-1 wild-type protease and of the inhibitors Indinavir, L-739,622 and Saquinavir with the mutant protease (9X) containing nine point mutations (Leu10Val, Lys20Met, Leu24Ile, Ser37Asp, Met46Ile, Ile54Val, Leu63Pro, Ala71Val, Val82Thr) have been determined. Comparative analysis of these structures reveals an alternate binding pocket for the P1-P3 group of Indinavir and L--756, 423. The alternate binding pocket is a result of concerted structural change in the 80s loop (residues 79-82) of the protease. The 80s loop is pulled away from the active site in order to accommodate the P1-P3 group, which is sandwiched between the flap and the 80s loop. This structural change is observed for the complexes of the wild type as well as the 9X mutant protease. The study reveals that the 80s loop is an intrinsically flexible loop in the wild-type HIV-1 protease and that mutations in this loop are not necessary to result in conformational changes. Conformation of this loop in the complex depends primarily upon the nature of the bound inhibitor and may be influenced by mutations in the protease. The results underscore the need to understand the intrinsic structural plasticity of the protease for the design of effective inhibitors against the wild-type and drug-resistant enzyme forms. In addition, the alternate binding pocket for the P1-P3 group of Indinavir and L--756,423 may be exploited for the design of potent inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739910     DOI: 10.1107/s0907444900000469

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  12 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  Inhibition and substrate recognition--a computational approach applied to HIV protease.

Authors:  H M Vinkers; M R de Jonge; E D Daeyaert; J Heeres; L M H Koymans; J H van Lenthe; P J Lewi; H Timmerman; P A J Janssen
Journal:  J Comput Aided Mol Des       Date:  2003-09       Impact factor: 3.686

3.  Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.

Authors:  Xianfeng Chen; Irene T Weber; Robert W Harrison
Journal:  J Mol Model       Date:  2004-09-28       Impact factor: 1.810

4.  Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

Authors:  José C Clemente; Roxana M Coman; Michele M Thiaville; Linda K Janka; Jennifer A Jeung; Sarawut Nukoolkarn; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Robert McKenna; Wichet Leelamanit; Maureen M Goodenow; Ben M Dunn
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

5.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

6.  Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.

Authors:  Jennifer E Foulkes; Moses Prabu-Jeyabalan; Deyna Cooper; Gavin J Henderson; Janera Harris; Ronald Swanstrom; Celia A Schiffer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Carbamylation of N-terminal proline.

Authors:  Folasade M Olajuyigbe; Nicola Demitri; Joshua O Ajele; Elisa Maurizio; Lucio Randaccio; Silvano Geremia
Journal:  ACS Med Chem Lett       Date:  2010-06-02       Impact factor: 4.345

8.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

9.  Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

Authors:  Nancy M King; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Piet Wigerinck; Marie-Pierre de Béthune; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Molecular Basis for Drug Resistance in HIV-1 Protease.

Authors:  Akbar Ali; Rajintha M Bandaranayake; Yufeng Cai; Nancy M King; Madhavi Kolli; Seema Mittal; Jennifer F Murzycki; Madhavi N L Nalam; Ellen A Nalivaika; Ayşegül Özen; Moses M Prabu-Jeyabalan; Kelly Thayer; Celia A Schiffer
Journal:  Viruses       Date:  2010-11-12       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.